Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Piloto (São Paulo (SP), Brazil), C. Fernandes (São Paulo (SP), Brazil), C. Jardim (São Paulo (SP), Brazil), M. Castro (São Paulo (SP), Brazil), W. Salibe-Filho (São Paulo (SP), Brazil), J. Alves-Jr (São Paulo (SP), Brazil), L. Morinaga (São Paulo (SP), Brazil), J. Sobral-Alves (São Paulo (SP), Brazil), S. Hoette (São Paulo (SP), Brazil), M. Terra-Filho (São Paulo (SP), Brazil), R. Souza (São Paulo (SP), Brazil). Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension. 1466

Member's Comments

No comment yet.

Related content which might interest you: The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade Source: Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017 Year: 2017 SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Potassium channels in pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 1167-1177 Year: 2015 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Prediction of effects of calcium channel blockers (CCB) on hypoxic pulmonary hypertension (HPH) due to COPD Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Role of NO pathway, calcium and potassium channels in the peripheral pulmonary vascular tone in dogs Source: Eur Respir J 2001; 17: 20-26 Year: 2001 Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018 Year: 2019 Long-term monitoring of respiratory function and influence of selective beta blockers on its decline in COPD patients with concomitant coronary heart disease Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Increased renin-angiotensin-aldosteron system activity in lungs of patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006